We are live on ! Find out more
BLPH

Bellerophon Therapeutics, Inc.
BLPH

Delisted

BLPH was delisted on the 13th of October, 2023.

Back to rankings

2 hedge funds and large institutions have $6.37K invested in Bellerophon Therapeutics, Inc. in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% less funds holding

Funds holding: 22 → 2 (-20)

99% less capital invested

Capital invested by funds: $507K → $6.37K (-$500K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 20

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-20
Holders Change %
-90.91%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
20
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Wells Fargo
Wells Fargo
California
-$71.6K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$64.1K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$58K
4
BlackRock
BlackRock
New York
-$50.8K
5
Two Sigma Investments
Two Sigma Investments
New York
-$45.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Acadian Asset Management
1
Acadian Asset Management
Massachusetts
$6K -$64.1K -183,578 -48%
RJA
2
Raymond James & Associates
Florida
$370 – – –
Wells Fargo
3
Wells Fargo
California
– -$71.6K -180,066 Closed
Vanguard Group
4
Vanguard Group
Pennsylvania
– -$58K -145,810 Closed
BlackRock
5
BlackRock
New York
– -$50.8K -127,723 Closed
Two Sigma Investments
6
Two Sigma Investments
New York
– -$45.3K -113,911 Closed
Geode Capital Management
7
Geode Capital Management
Massachusetts
– -$38.3K -95,656 Closed
Renaissance Technologies
8
Renaissance Technologies
New York
– -$24K -59,499 Closed
Citadel Advisors
9
Citadel Advisors
Florida
– -$17.1K -42,717 Closed
Northern Trust
10
Northern Trust
Illinois
– -$12K -30,251 Closed
State Street
11
State Street
Massachusetts
– -$12.1K -30,127 Closed
Two Sigma Advisers
12
Two Sigma Advisers
New York
– -$8.55K -21,500 Closed
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
– -$6.13K -15,313 Closed
TRCT
14
Tower Research Capital (TRC)
New York
– -$2.84K -7,135 Closed
PP
15
PFS Partners
New Jersey
– -$2.39K -6,000 Closed
Group One Trading
16
Group One Trading
Illinois
– -$840 -2,100 Closed
US Bancorp
17
US Bancorp
Minnesota
– -$485 -1,221 Closed
Osaic Holdings
18
Osaic Holdings
Arizona
– -$221 -557 Closed
Qube Research & Technologies (QRT)
19
Qube Research & Technologies (QRT)
United Kingdom
– -$21 -52 Closed
GWSA
20
Global Wealth Strategies & Associates
Colorado
– -$20 -50 Closed
GWSG
21
GPS Wealth Strategies Group
Colorado
– -$15 -38 Closed
Morgan Stanley
22
Morgan Stanley
New York
– -$13 -33 Closed

BLPH Hedge Fund Activity: Q4 2023 in Review

2 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q4 2023, worth a combined $6.37K — down 99% from $507K a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of BLPH and 0 opened new positions — a net loss of 20 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Wells Fargo, exiting entirely with an estimated $71.6K sold.

  • 2 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q4 2023, down from 22 in Q3 2023.
  • Funds reported $6.37K of Bellerophon Therapeutics, Inc. stock for Q4 2023, down 99% quarter-over-quarter.
  • 0 funds opened new Bellerophon Therapeutics, Inc. positions in Q4 2023 and 20 closed out, a net change of -20 holders.
  • The largest Bellerophon Therapeutics, Inc. seller in Q4 2023 was Wells Fargo, an estimated $71.6K sold.

Based on aggregated 13F filings for Q4 2023.